Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer


Abstract

The management of pancreatic ductal adenocarcinoma (PDAC) is extremely poor due to lack of an efficient therapy and development of chemoresistance to the current standard therapy, gemcitabine. Recent studies implicate the intimate reciprocal interactions between epithelia and underlyingstroma due to paracrine Sonic hedgehog (SHH) signaling in producing desmoplasia and chemoresistance in PDAC. Herein, we report for the first time that a nonsteroidal drug, ormeloxifene, has potent anticancer properties and depletes tumor-associated stromal tissue by inhibiting the SHH signaling pathway in PDAC. We found that ormeloxifene inhibited cell proliferation and induced death in PDAC cells, which provoked us to investigate the combinatorial effects of ormeloxifene with treatment alone or in combination with gemcitabine. We propose that ormeloxifene has high therapeutic index and in a combination therapy with gemcitabine, it possesses great promise as a treatment of choice for PDAC/pancreatic cancer.

Introduction

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis largely due to its propensity for early local invasion, distant metastasis, and lack of effective therapies. Many chemotherapeutic regimens have failed and the current standard-of-care therapy, gemcitabine, extends patient survival by only a few months (1). Newer treatment options for PDAC patients are FOLFIRINOX and nab-paclitaxel/gemcitabine, which improved overall survival by 4.3 and 1.8 months over gemcitabine therapy, respectively (2, 3).

However, safety profile of these drugs is less favorable than gemcitabine therapy, accounting for myelosuppression and peripheral neuropathy (2–4). Despite these advances, the overall outcome remains miserable for this patient population. Thus, investigations on alternative approaches for PDAC therapy are a high research priority.

Activation of oncogenes, such as Kras, and/or inactivating mutations or loss of expression of tumor-suppressor genes (including DPC4, p16, p53, and SMAD4) is known in PDAC (5). It has been shown that extensive desmoplasia is one of the underlying causes of pancreatic cancer’s poor prognosis and chemoresistance (6). Desmoplasia is typically characterized by excessive production of extracellular matrix (ECM) and collagen I and is associated with proliferation of stromal cells, myofibroblasts, and pancreatic stellate cells. A profound role of Sonic hedgehog (SHH) pathway is implicated in desmoplasia (7) and cancer progression (8), including PDAC (9). This developmental pathway, dormant in the adult pancreas, becomes reactivated early in PDAC development (10). SHH is a member of the Hedgehog (Hh) family of secreted signaling proteins, having diverse functions during vertebrate development (11). In pancreatic tumors, intimate reciprocal interactions occur between epithelia and underlying stroma due to paracrine Hh signaling that lead to desmoplasia and form a barrier to chemotherapy drug(s) penetration (12). Depletion of tumor stroma leads to the increasing functional vasculature that provides a feasible avenue for efficient therapeutic drug delivery (13). In addition, Hh signaling...
plays a key role in the maintenance of pancreatic cancer stem cells (CSC) that are involved in drug resistance, cancer recurrence, and poor clinical outcome (10). Therefore, molecular and/or chemical intervention to target Hh signaling and disruption in the microenvironment in tumors could be an interesting therapeutic approach for pancreatic cancer (13). Some of the well-known Hh signaling antagonists, such as vismodegib (GDC-0449), have been investigated alone or as an adjuvant to the traditional anticancer drugs but have not yielded clinically meaningful results (14, 15) and have shown notable adverse effects including teratogenic properties (16, 17). Thus, identification of novel therapies with high therapeutic index that can target Hh and tumor progression signaling pathways with no or minimal adverse effects is required.

Repurposing of established drugs as anticancer agents is a current active investigative approach. Ormeloxifene is a non-hormonal, nonsteroidal, and nonconceptive molecule. Recent studies suggested that ormeloxifene may be effective in inhibiting breast cancer, head and neck cancer, and chronic myeloid leukemia cells (18). Moreover, ormeloxifene is reported to have an excellent therapeutic index and is safe for chronic administration (19). This study demonstrates the inhibitory role of ormeloxifene on the SHH signaling pathway, and describes inhibitory patterns of this drug on pancreatic tumor progression using bidirectional tumor stromal interactions. This inhibitory effect was either more pronounced or comparable with a known smoothened (SMO) inhibitor, GDC-0449, in PDAC cells. Ormeloxifene disrupts the stroma of fibrotic pancreatic tumors and inhibits the proliferating stellate and myeloid cells involved in the development of pancreatic fibrosis. Furthermore, the combinatorial effects of ormeloxifene with gemcitabine induce increased gemcitabine sensitivity. In addition, these studies also suggest wide use of ormeloxifene in PDAC patients due to its intended safe use in fertile women, considering the teratogenic potential of other Hh pathway inhibitors such as cyclophosphamide and GDC-0449 (20, 21).

Materials and Methods

Cell culture, growth conditions, and treatments

Cell lines were purchased from the ATCC and were maintained at 37°C/5% CO2 in recommended growth medium with 10% FBS (RPMI, DMEM and DMEM/Ham’s F12; Hyclone Laboratories). Human CSCs (CD133+/CD44+/CD24−/ESA+) were obtained from Celprogen Inc. They were isolated from primary tumors and have been described previously (22). All cell lines were maintained in continuous exponential growth by twice a week passaging in cell type-specific media. Ormeloxifene was generously synthesized and provided by Fathi Halaweish (South Dakota State University, Brookings, SD) as described earlier (23). Gemcitabine was purchased from Sigma-Aldrich (cat. no. G6423) and GDC-0449 from Sellekchem (cat. no. S1082). Cells were treated with indicated doses of ormeloxifene, gemcitabine, and GDC-0449 after completely solubilized in ethanol, PBS, and DMSO, respectively.

Cell proliferation by MTS assay

The antiproliferative effect of ormeloxifene was determined after 48 hours using the CellTiter 96 AQueous One solution assay (cat. G5421; Promega) using a microplate reader (BioMate 3 UV-Vis spectrophotometer; Thermo Electron Corporation). Ethanol- or PBS-containing medium served as the vehicle control. In addition, the antiproliferative effect of ormeloxifene was determined at 24 and 48 hours using Cell Counting Kit-8 (Mayflower Bioscience) and the percentage viability of Panc-1 and BxPC-3 cells was determined after treatment with GDC-0449 and ormeloxifene. The antiproliferative effect of each treatment was calculated as a percentage of cell growth with respect to the vehicle control.

Cell proliferation by xCELLigence assay

PDAC cells (10,000 cells/well) were seeded in E-plate (Roche) following the xCELLigence Real Time Cell Analyzer (RTCA) DP instrument manual as provided by the manufacturer (Roche; ref. 24). After 24 hours, ormeloxifene or the vehicle control was added and the experiment was allowed to run for 100 hours. Average baseline cell index for ormeloxifene-treated cells compared with control cells was calculated for at least two measurements from three replicated experiments.

Flow cytometric analysis of apoptosis and necrosis

BxPC-3 and Panc-1 cells (1 × 106) were treated for 24 hours with ormeloxifene (15 μmol/L) and gemcitabine (100 nmol/L) alone and in combination. Cells were stained with Annexin V–FITC and propidium iodide (PI). The apoptotic and necrotic populations were detected as described earlier (25). Cells were scanned in FL-1 (FITC) versus FL-2 (PI) channels and analyzed using an Accuri C6 flow cytometer (Accuri Cytometers, Inc.).

Cell-cycle analysis

Cells were exposed to ormeloxifene (15 μmol/L) and gemcitabine (100 nmol/L) alone or in combination for 24 hours and stained with Telford Reagent containing PI (cat. no. P-4170; Sigma-Aldrich). Cells were analyzed with an Accuri C6 flow cytometer. Cells with hypodiploid DNA (content less than G0−G1) were deemed apoptotic (sub-G0−G1).

Dual-Luciferase reporter assay

Dual-Luciferase reporter assay was carried out to investigate the effect of treatments on Gli-1 and NFκB transcriptional activity using a luciferase assay kit (cat. no. E2940; Promega) according to the manufacturer’s protocol. BxPC-3 and Panc-1 cells were transfected with luciferase reporter constructs [NF-kB, gift from Dr. Ajay Singh, Mitchell Cancer Institute, Fairhope, AL; Cignal GLI Reporter (Luc) Kit, cat. no. CCS-6030L; Qiagen] and treated with ormeloxifene and gemcitabine alone or in combination for 24 hours. The normalized luciferase activity was expressed as a ratio of firefly luciferase to Renilla luciferase units.

Indirect coculture of PDAC cells and pancreatic stromal cells

Human pancreatic stromal cell (PSC) fibroblasts and stellate cells were obtained from an islet transplant program and maintained in CMRL-1066 medium (cat. no. 15110; Corning) supplemented with 10% FBS, penicillin sodium, and streptomycin sulfate at 37°C in humidified atmosphere containing 5% CO2. Human PSCs (3 × 10⁶ cells/culture insert) were seeded into the culture inserts of 1.0-μm pore size (BD Biosciences) in CMRL-1066 media. On day 2, the culture inserts were placed into 6-well plates containing Panc-1 cells (0.8 × 10⁶ cells/well), followed by treatment with ormeloxifene (10 μmol/L) and gemcitabine (100 nmol/L) and incubated up to 2 days in DMEM medium. As previous studies have shown TGFβ to be a potent inducer of epithelial–mesenchymal transition (EMT) in several cancer cells including pancreatic cancer cells (26, 27), we used recombinant...
TGFB (2 ng/mL) to stimulate the stromal cells as a mediator of PSC-induced EMT in cells.

Clonogenic assay
For the clonogenic assay, 500 cells were treated with indicated concentrations of ormeloxifene for 12 days. The visible colonies (≥ 50 cells) were counted following hematoxylin staining (Fisher Scientific) and the percentage of colonies was calculated as compared with control, as described earlier (28).

Cell motility, migration, and invasion assays
Cell motility was analyzed with a Boyden’s chamber assay (28). For cell invasion assays, BD BioCoat Matrigel Invasion Chambers (BD Biosciences) were used as per the manufacturer’s instructions. After 48 hours of incubation, the invading cells were stained and counted in 10 fields of view. In addition, a wound-healing migration assay was also used to evaluate the effect of ormeloxifene on the migratory ability of cancer cells. The cell monolayer was scraped using a micropipette tip and 48 to 72 hours after treatment, the residual gap length was calculated from photomicrographs. To further confirm these findings, real-time migration and proliferation were performed by the xCELLigence system, which is an electrical impedance-based method that allows for the measurement of cell migration and proliferation in real-time (24).

For the clonogenic assay, 500 cells in 200 μL PBS/Matrigel subcutaneously. On day 15, the mice were treated with vehicle (ethanol), ormeloxifene (200 μg), gemcitabine (500 μg), or their combination via i.p. injections, three times a week, for 6 subsequent weeks. Mice were weighed twice a week to monitor their health and tumor growth. Tumor volume (V) was estimated from the length (l), width (w), and height (h) of the tumor using the formula $V = \frac{1}{2} l \times w \times h$, as described previously (Supplementary Fig. S4; ref. 28). Forty-five days after the first drug injection, mice were euthanized and tumor burden (wet weight) and metastases were noted. The organs, including pancreas, were harvested and checked for metastases. The data were modeled with time (discrete), group (control, ormeloxifene, gemcitabine, and ORM+GEM), and the interaction between them. Primary analyses involved planned comparisons (separately for each time point) between control and ormeloxifene/gemcitabine versus ORM+GEM. Animal care was performed in accordance with institutional guidelines and all animal experiments were carried out using protocols approved by the Sanford Research Institutional Animal Care and Use Committee.

**In situ** hybridization for microRNA detection and expression
We detected the expression of miR-132 in formalin-fixed paraffin-embedded (FFPE) tissues of control and treated xenograft mice. We used an **in situ** hybridization technique and used a Biochain kit (cat. no. K2191050; Biochain IsHyb In Situ hybridization kit) as previously described (29). Briefly, tissues were hybridized with hybridization buffer and digoxigenin-labeled probe (EXIQON) at 45°C overnight followed by incubation with the AP-conjugated anti-digoxigenin antibody and NBT/BCIP (Pierce) and nuclear fast red counterstaining.

**Immunofluorescence and immunohistochemical analyses**
Immunofluorescence and IHC analyses were used to analyze the untreated and treated xenograft tumor tissues to detect changes associated with the expression of important proteins involved in tumor–stromal interactions as described previously (30). The slides were stained with specific antibodies following heat-induced antigen retrieval techniques and imaged using a laser scanning confocal microscope (Nikon TIRF) with a ×200 Aplanochromat objective for immunofluorescence. For immunohistochemistry, the slides were stained using Biocare’s MACH4 Universal HRP-Polymer kit (Biocare Medical) and analyzed as previously described (29, 30).

**Statistical analyses**
Statistical significance of the studies was analyzed by the Student *t* test. Differences with *P* values of < 0.05 are considered significant. Tumor size values were examined at the day 50 point, using an ANOVA approach. Tests of main effects (differences between treatments) and contrasts were performed.

**Results**
Ormeloxifene treatment suppresses tumorigenic features of PDAC cells
Ormeloxifene was found to have an anticancer effect on all tested PDAC cells (Fig. 1A and Supplementary Fig. S1A). To confirm these results, we measured the growth in real time for
duration of 100 hours using the xCELLigence system (Fig. 1B). This assay monitors cell growth in real time by measuring changes in electric impedance between two golden electrodes embedded in the bottom of the cell culture wells. The impedance, which is directly proportional to the number of cells and also re

converted to a cell index value, is directly proportional to the electric impedance between two golden electrodes embedded in the bottom of the cell culture wells. The impedance, which is also referred to as the cell index value, is directly proportional to the number of cells in the well. The cell index value is a measure of the cell number and its change over time. The cell index value is calculated as the ratio of the impedance of the well containing the cells to the impedance of a blank well. The impedance is measured at regular intervals and the cell index value is plotted against time to generate a growth curve. The growth curve is used to determine the ability of cells to form colonies (percentage inhibition) following treatment. Cells were photographed and counted using AlphaEaseFC (Alpha ImagerHP AIC) software analysis tool. Bars represent mean ± SD; n = 3; * P < 0.05; ** P < 0.001.

Figure 1. Determination of proliferation, clonogenicity, and cytotoxicity profiles of ormeloxifene in PDAC cells. A, structure of ormeloxifene (UPAC name: 1-[2-[4-[[3,4R)-7-methoxy-2,2-dimethyl-3-phenyl-chroman-4-yl]phenoxy]ethyl]pyrrolidine) and its effect on cell growth was monitored using the MTS assay for 48 hours and is shown as percentage. B, effect of ormeloxifene on cell proliferation with respect to time was also confirmed by xCELLigence RTCA. The assay indicated that ormeloxifene significantly reduced the baseline cell index compared with the control cells (Fig. 1B). Furthermore, ormeloxifene treatment inhibited the clonogenic potential of PDAC cells (BxPC-3, Panc-1, AsPC-1, MiaPaca, and HPAF-II) as evident by the decreased number of colonies after ormeloxifene treatment (Fig. 1C). Moreover, ormeloxifene was also found to inhibit cellular motility (Fig. 2A) and invasion (Fig. 2B) of PDAC cells. The inhibition of the migratory ability of cells is demonstrated by wound-healing assay (Supplementary Fig. S1B) and cellular invasion by Matrigel invasion assay (Supplementary Fig. S1C), which was further confirmed using the xCELLigence method (Fig. 2C).

In addition, we sought to compare the anticancer potential of ormeloxifene with a known SMO inhibitor (GDC-0449) in human PDAC cells. Ormeloxifene showed more pronounced or comparable inhibitory effect on cell proliferation, clonogenicity, and invasion than GDC-0449 at equal indicated concentrations (Supplementary Fig. S2A–S2C). Inhibition of cell viability and invasion was observed within 48 hours following exposure to these drugs.

Ormeloxifene treatment inhibits tumorsphere formation in pancreatic stem cells

We observed a significant effect of ormeloxifene on tumorsphere formation in CSCs as reflected by a reduction in size and number of tumorspheres in cells upon treatment, suggesting the clonogenic depletion of the CSCs. In contrast, GDC-0449 did not show a significant effect on secondary tumorsphere formation (Supplementary Fig. S2D).

Ormeloxifene inhibits SHH signaling in PDAC cells

The SHH signaling pathway has been implicated in the development of pancreatic cancer (9). Therefore, PDAC cells were treated with ormeloxifene and changes in the SHH signaling pathway were evaluated by Western blot and qRT-PCR analyses. Ormeloxifene treatment effectively inhibited SHH expression at protein and mRNA levels at indicated concentrations (Figs. 2D and Supplementary Fig. S3A and S3B). Ormeloxifene treatment also inhibited the expression of Gli-1, SMO, cyclin D1, and p-AKT, the
key downstream proteins that drive the oncogenic signaling of SHH pathway in BxPC-3 and MiaPaca cells (Fig. 2D and Supplementary Fig. S3A; ref. 12). Ormeloxifene treatment also increased the expression of tumor-suppressor SUFU, which interacts directly with Gli-1 proteins to repress SHH signaling (Fig. 2D and Supplementary Fig. S3A; ref. 32).

Importantly, ormeloxifene treatment caused a marked (>70%) decrease in the expression of the SHH transcription factor, NF-κB-65 (33), and its downstream target, cyclin D1 (34), within 24 hours (Fig. 2D and Supplementary Fig. S3C). Cyclin D1 is an important mediator of SHH-induced cell proliferation and carcinogenesis. These data suggest that ormeloxifene treatment effectively inhibits tumorigenic phenotypes via modulation of SHH and its downstream signaling molecules.

Ormeloxifene and gemcitabine in combination induce apoptosis in PDAC cells

We investigated whether ormeloxifene treatment enhanced the apoptotic index in gemcitabine-resistant PDAC cells (Panc-1 and BxPC-3). Our data show that when combined, ormeloxifene (15 μmol/L) and gemcitabine (100 nmol/L) induced a significantly higher (21%) apoptotic population in 24 hours as compared with
Ormeloxifene and gemcitabine treatment alone (Fig. 3A). However, PI-positive postapoptotic/necrotic cell population was relatively small, suggesting that the induced cytotoxicity was predominantly through activation of apoptotic pathways. These data suggest that ormeloxifene-alone induced cell death does not involve the release of phosphatidylserine onto the outer leaflet,
indicative of Annexin V–positive apoptotic cells and mitochondrial apoptotic signaling. Instead, it may involve death receptor–mediated extrinsic apoptotic signaling. Therefore, we sought to investigate the effect of ormeloxifene on cell-cycle phase distribution. Typically, D-type cyclins are required for the progression of cells from the G1-phase of the cell cycle to S-phase (35). Ormeloxifene treatment decreased the expression of cyclin D in BxPC-3 and MiaPaca cells (Fig. 2D and Supplementary Fig. S3A). Ormeloxifene treatment led to cell-cycle arrest at sub-G0–G1 phase in Panc-1 and BxPC-3 cells. Cells in sub-G1-phase increased up to 74% after ormeloxifene treatment (15 μmol/L), while cells in the S-phase decreased from 19% to 5%. However, gemcitabine treatment did not show an additional effect on cell-cycle phases (Fig. 3B). Similar effects in cell-cycle phase distribution were observed in BxPC-3 cells, which showed significant inhibition of the G2–M phase upon treatment with ormeloxifene and gemcitabine in combination.

Ormeloxifene and gemcitabine combination targets SHH signaling pathway and inhibits CIL in PDAC cells

In addition, we investigated combinatorial effects of ormeloxifene and gemcitabine on SHH and downstream signaling molecules. Treatment with ormeloxifene and gemcitabine has relatively more pronounced inhibitory effects on the expression of SHH, Gli-1, and SMO as compared with ormeloxifene or gemcitabine alone (Fig. 3D). This reveals the potentiated effects of ormeloxifene in combination with gemcitabine. We also confirmed these results by qRT-PCR analysis and observed an apparent decrease in the mRNA levels of main effectors of the SHH signaling pathway in response to ormeloxifene alone or in combination with gemcitabine. This included decreased expression of SHH (4-fold), SMO (5-fold), and patched 1/2 (PITCH1/2) compared with the control (Fig. 3C). Ormeloxifene alone or in combination with gemcitabine also showed a marked (~40%) decrease in the level of antiapoptotic, Bcl-xl protein (Fig. 3D). The Bcl-xl protein is also an important mediator of SHH and is transcriptionally regulated by SHH through the Gli-1 transcription factor (34). In addition, ormeloxifene alone or in combination with gemcitabine inhibited the Gli-1 and Nf-κB-B-65 transcriptional activity in PDAC cells (Fig. 4A and Supplementary Fig. S3C). These results present first evidence that ormeloxifene inhibits the SHH–Gli-1 signaling pathway in PDAC.

Moreover, we evaluated the ability of ormeloxifene and gemcitabine to inhibit tumor progression and found that ormeloxifene inhibited motility (Fig. 4B) and the migratory ability of PDAC cells as demonstrated by wound healing (Fig. 4C).

Ormeloxifene and gemcitabine combination efficiently abrogates TGFβ-induced SHH signaling

The interactions among the stromal and tumor cells and the various cytokines embedded in the ECM contribute to the neoplastic phenotype (36). In addition to the activated tumor-stromal myofibroblasts (characterized by the expression of contractile genes such as smooth-muscle actin, αSMA; ref. 37), the activated PSCs that are characterized by expression of the stellate cell activation-associated protein (cygb/STAP) are identified as the major source of the excessive stromal ECM production in pancreatic tumors (6). Here, we show for the first time that indirect coculture of PDAC cells with PSCs (stimulated with TGFβ) induced enhanced secretion of SHH and chemokine CXCL12 (stromal cell–derived factor-1, SDF1) that was abrogated by ormeloxifene alone or in combination with gemcitabine. Gemcitabine treatment alone did not show any effect as observed through ELISA of the conditioned media in which the PDAC cells were cultured (Fig. 4D). CXCL12 is abundantly produced by the stromal cells that induce SHH expression, which promotes progression, metastasis, and chemoresistance of PDAC cells (38).

In addition, treatment with ormeloxifene alone or in combination inhibited the proliferation of PSCs as depicted by the decreased expression of αSMA and cygb/STAP in the immunofluorescence of PSCs (Fig. 4D, bottom). These results suggest that ormeloxifene not only reduces the number of stromal cells involved in the development of pancreatic fibrosis but also inhibits the paracrine SHH signaling between cancer and stromal cells that leads to desmoplasia and causes chemoresistance.

Combined ormeloxifene and gemcitabine treatment effectively inhibits tumor burden in mice model

To investigate the anticancer effects of ormeloxifene, we used a subcutaneous (for solid tumor) and i.p. (metastatic) preclinical murine xenograft model generated with gemcitabine-resistant BxPC-3 cells. Both ormeloxifene and gemcitabine, administered alone, inhibited overall tumor burden, but combination treatment of the two was more efficacious than either of them alone (Fig. 5A and B). When compared with the control mice, mice treated with ormeloxifene (P = 0.0301) or gemcitabine (P = 0.0009) or ORM + GEM in combination (P < 0.0001) showed a marked reduction in tumor weight (Fig. 5B). Moreover, in the i.p. model, tumors barely developed in the ORM + GEM–treated group. Upon further examination, we also found there were fewer or no metastases in the mice treated with ormeloxifene alone or in combination with gemcitabine (Fig. 5B, inset table). miR-132 is downregulated in pancreatic cancer, which contributes to pancreatic cancer development (39). Treatment of ormeloxifene alone or in combination with gemcitabine leads to increased levels of miR-132 in xenograft tumors (Fig. 5C). These data further confirm that ormeloxifene treatment along with gemcitabine could be an effective therapeutic modality for pancreatic cancer.

Ormeloxifene inhibits tumor desmoplasia and the host cells invading the tumor

To elucidate the basis of the potentiated antitumorigenic effects of ormeloxifene in combination with gemcitabine in mice, we analyzed the FFPE tumor tissues through tumor histopathology, immunofluorescence, and IHC analyses. We observed a clear inhibition of Gli-1 expression in tumor tissues from mice treated with either ormeloxifene alone or in combination with gemcitabine (Fig. 5D). In contrast to vehicle- or gemcitabine-treated mice, which exhibited profuse desmoplastic tumor stroma, mice treated with ormeloxifene showed markedly depleted desmoplastic stroma. This was evidenced by a decrease in collagen I content in tumor xenografts and the invading host mice cells migrating into the tumors (Fig. 6A). It was found that only ormeloxifene, but not gemcitabine, reduced the amount of collagen I deposition. Interestingly, these differences were apparent in mice treated with ormeloxifene or ORM + GEM. In addition, ormeloxifene alone or in combination with gemcitabine treatment showed decreased number of activated stromal cell populations as identified by the reduced expression of αSMA and fibroblast surface protein (FSP)–positive stromal myofibroblasts (Fig. 6A) and cygb/STAP positive activated stellate cells (Fig. 6B; ref. 37). Gemcitabine alone treatment did not show any effects on these parameters. This decrease
in proliferation was accompanied by a decrease in SHH expression in ormeloxifene and ORM-GEM–treated tumor tissues (Fig. 6B). Furthermore, we analyzed these tumor tissues for the presence of tumor-infiltrating macrophages and found a large increasing population of macrophages in ormeloxifene-treated mice tumor tissues (Fig. 6B) that might become tumoricidal and facilitate the depletion of the tumor stroma (40, 41). This signifies that ormeloxifene alone or in combination with gemcitabine inhibits the host cells invading the tumor tissue and disrupts the desmoplastic stroma that can facilitate the delivery and enhance the efficacy of gemcitabine.

Discussion

Pancreatic tumors are typically characterized by a high desmoplastic reaction (42). Desmoplasia plays an important role to initiate cross-talk between stromal-cancer cells, limit the delivery and effectiveness of chemotherapy, and induce chemoresistance. The SHH pathway is a major player for desmoplasia and is activated in both stromal and cancer cells in PDAC (7, 43). Therefore, suppression of the Hh pathway and desmoplasia may limit the molecular/clinical course of PDAC and improve drug(s) access in tumors (13). Currently available Hh pathway antagonists, including GDC-0449, have been investigated as a single agent or in combination with conventional chemotherapies for cancer treatment (14, 15). GDC-0449 is an SMO (Hh) inhibitor approved by the FDA for the treatment of locally advanced and metastatic basal cell carcinomas. But severe toxicity issues and adverse effects (fatigue, nausea, asthenia, mucositis, peripheral sensory neuropathy, dysgeusia, muscle spasms, and dehydration) and the lack of strong efficacy, limits its use in cancer therapy (44). In addition, no significant improvement in survival of pancreatic, colon, and ovarian cancer patients is noticed in recent clinical trials of Hh signaling inhibitors. As other signaling pathways
such as PI3K or TGFβ signaling; refs. 45, 46) are also known to activate transcriptional activity of Gli in addition to SMO, the therapeutic efficacy of SMO inhibitors is compromised in cancer. This is a probable rationale for shifting interest from SMO inhibitors toward more specific Gli inhibitors in order to effectively suppress the Hh signaling pathway. In this endeavor, we have identified ormeloxifene, a nonsteroidal triphenylethylene compound that effectively blocks the Hh signaling pathway by inhibiting the important effectors of this pathway, such as SHH, SMO, Gli-1, and SDF-1 (CXCL12). Ormeloxifene disrupts multiple paracrine factors that are important for the maintenance of Hh signaling, and thus inhibits stromal and tumor cell cross-talk within the tumor.

Experimental investigations indicate that ormeloxifene inhibits proliferation, invasion, and clonogenicity of PDAC cells (Fig. 1 and Supplementary Fig. S2), comparable with cells treated with GDC-0449. In addition, reduced tumorsphere formation of CSCs that were treated with ormeloxifene indicates that ormeloxifene also inhibits pancreatic CSC proliferation and self-renewal. This suggests that the anticancer effects of ormeloxifene are greater or comparable with GDC-0449. Investigations of the mechanism of ormeloxifene-induced cell death showed the induction of cell-

<table>
<thead>
<tr>
<th>Treatment</th>
<th>Mice (n)</th>
<th>Mean volume (mm²) of secondary tumors</th>
<th>Mean tumor weight (gm) (pr+sec)</th>
<th>No. of mice with dissemination to intestine</th>
<th>No. of mice with dissemination to pancreas</th>
<th>No. of mice with dissemination to liver</th>
<th>Av. metastases</th>
</tr>
</thead>
<tbody>
<tr>
<td>EtOH</td>
<td>6</td>
<td>210.1</td>
<td>2</td>
<td>6</td>
<td>1</td>
<td>3</td>
<td>22.5</td>
</tr>
<tr>
<td>ORM</td>
<td>6</td>
<td>9.2†</td>
<td>1.2</td>
<td>0*</td>
<td>0*</td>
<td>2*</td>
<td>7.5†</td>
</tr>
<tr>
<td>GEM</td>
<td>6</td>
<td>55.9†</td>
<td>0.6†</td>
<td>0*</td>
<td>0*</td>
<td>0*</td>
<td>0*</td>
</tr>
<tr>
<td>ORM + GEM</td>
<td>6</td>
<td>19.6*†</td>
<td>0.2*</td>
<td>0*</td>
<td>0*</td>
<td>0*</td>
<td>0*</td>
</tr>
</tbody>
</table>

*Significantly different from EtOH group (P < 0.0001), †Significantly different from EtOH group (P < 0.01)
"'Significantly different from EtOH group (P < 0.001), #Significantly different from GEM group (P < 0.01)
$Significantly different from ORM group (P < 0.01)

Figure 5. Ormeloxifene and gemcitabine in combination inhibit tumor growth in pancreatic xenograft mice. A, photographs of xenograft mice from each treatment group. B, average tumor volume and average tumor weight was determined. Bars represent mean ± SD; *, P < 0.01; **, P < 0.0001. The corresponding table shows the effect of ormeloxifene on tumor development and dissemination. C, in situ hybridization for tumor-suppressor miR-132 was performed on the excised tumor tissues from treated mice. D, IHC staining showing the inhibition of Gli-1 expression in tumor tissues from mice treated with ormeloxifene alone or with gemcitabine. Images were captured using Nikon phase contrast microscope with >200 objective.

ORM, ormeloxifene; GEM, gemcitabine.
cycle arrest at G0–G1 phase, suggesting that ormeloxifene may induce apoptosis. It was also an intriguing observation that treatment of ormeloxifene in combination with gemcitabine showed an increasing population of Annexin V–positive cells as compared with when both were used alone. These results indicate that in the presence of ormeloxifene, gemcitabine induces higher apoptotic cell death that might be triggered through the mitochondrial pathway. Alternatively, the other possibility is that ormeloxifene might involve death receptor–mediated cell death.

Altogether, the results indicated that ormeloxifene potentiates the anticancer effect of gemcitabine when used in combination. It has been reported that NF-κB (33) and SHH (7, 43) signaling pathways play crucial roles in PDAC progression and drug resistance, including gemcitabine. Ormeloxifene treatment stabilizes IκBα, which inhibits protein and transcriptional activity of NF-κB-65, preventing it from binding to the SHH promoter and leading to its transcription (33). This was further confirmed on finding that ormeloxifene alone or in combination with gemcitabine inhibits the main downstream targets of SHH, SMO, and PTCH1/2 and downregulates the expression and transcriptional activity of Gli-1 in PDAC cells. No such effects were found in cells when treated with gemcitabine alone. In the absence of SHH, cells have small amounts of PTCH1/2 and Gli and therefore, the high concentrations of these transcripts generally indicate involvement of the SHH pathway in PDAC (47). The aberrantly activated SHH binds to its receptor PTCH1/2 and inhibits the suppressive effect of PTCH1/2 on SMO, which activates Gli-1 to transcribe Hh oncogenic target genes (43). Ormeloxifene inhibits AKT phosphorylation, which is known to activate Gli-1 (48). The observations collected from coculturing the PDAC cells with stromal cells indicate the inhibition of paracrine stromal cell signaling through the inhibition of their proliferation and secretion of SHH and SDF1. All these results confirm that ormeloxifene inhibits Hh signaling in PDAC cells; thus, we hypothesized that it might also disrupt the stroma of pancreatic tumors and alter the desmoplastic reaction.

Recent studies implicate the profound role of stroma in drug resistance in numerous tumor types (49). Thus, treatments targeting both neoplastic cells and stromal components are emerging for PDAC (50). The enhanced antitumor effect of ormeloxifene and gemcitabine combination treatment was observed in xenograft mouse models when compared with their treatment alone. An abundant stromal component was observed in the control and gemcitabine-treated tumor tissues while mice treated with ormeloxifene alone or ORM+GEM combination showed markedly less stromal component and invaded stromal tissue. This was indicated by the presence of reduced numbers of stroma myofibroblasts infiltrating the tumor tissue, as indicated by reduced myofibroblasts expressing αSMA and cygb/STAP expression in the tumors obtained from ormeloxifene-treated mice. The increasing macrophage recruitment to tumor site can be explained as the emergence of tumor immunity that serves as a part of immune surveillance for targeting tumor stroma in the treatment of cancer. The activated macrophages may rapidly infiltrate the tumors, become tumoricidal and facilitate the depletion of tumor stroma.

These findings suggest that ormeloxifene inhibits desmoplastic reaction in PDAC. Due to the toxicity and morbidity of available drugs, there is an urgent need for effective therapies that could target both tumor and stromal compartments to regulate pancreatic tumor growth. Therefore, ormeloxifene might be a drug of choice as it is very safe for chronic use in humans. Our results signify that ormeloxifene is effective in targeting Hh and tumor progression signaling pathways. Our results emphasize that ormeloxifene interrupts the tumor–stromal interactions to inhibit the reciprocal relationship between these two components, leading to
reduction of tumor progression, invasion, metastasis, and che-
moresistance (Fig. 7). This facilitates the anticancer effects of
ormeloxifene and potentiates the chemotherapeutic effects of
gemcitabine for pancreatic cancer treatment. Our results have
important implications toward the development of effective
therapy for pancreatic cancer treatment.

Conclusion
In summary, our study provides new evidence regarding the
anticancer effects of ormeloxifene in PDAC. This study demon-
strates novel role of an existing drug, ormeloxifene to inhibit
the SHH pathway and desmoplasia, resulting in tumor growth
inhibition and potentiation of the antitumor effect of gemcita-
bine. This suggests that a combination of ormeloxifene and
gemcitabine may have the capacity to inhibit the SHH signaling
cascade in PDAC cells and alter the behavior of surrounding
stromal cells so that cancer progression is repressed. Therefore,
this study provides evidence that ormeloxifene in combination
with gemcitabine could serve as a novel therapeutic intervention
for pancreatic cancer.

Disclosure of Potential Conflicts of Interest
No potential conflicts of interest were disclosed.

Authors’ Contributions
Conception and design: S. Khan, M.M. Yallapu, S.W. Behrman, M.M. Singh,
M. Jaggi, S.C. Chauhan
Development of methodology: S. Khan, M.M. Yallapu, S.C. Chauhan

Acquisition of data (provided animals, acquired and managed patients,
provided facilities, etc.): S. Khan, M.C. Ebeling, N. Chauhan, R.K. Gara,
M.M. Yallapu, S.C. Chauhan
Analysis and interpretation of data (e.g., statistical analysis, biostatistics,
computational analysis): S. Khan, N. Chauhan, P.A. Thompson, R.K. Gara,
A. Ganju, S.W. Behrman, M. Jaggi, S.C. Chauhan
Writing, review, and/or revision of the manuscript: S. Khan, P.A. Thompson,
M.M. Yallapu, S.W. Behrman, M.M. Singh, S.C. Chauhan
Administrative, technical, or material support (i.e., reporting or organizing
data, constructing databases): S. Khan, H. Zhao, N. Zafar, M. Jaggi,
S.C. Chauhan
Study supervision: M. Jaggi, S.C. Chauhan

Acknowledgments
The authors thank the Komen Foundation for pancreatic cancer research
support. The authors are also thankful to Cathy Christopherson (Sanford
Research) for editorial assistance.

Grant Support
This work was partially supported by grants from Department of Defense
(PC073887 to S.C. Chauhan and PC073643 to M. Jaggi), the NIH (RO1
CA142736 to S.C. Chauhan), Pilot grant to S. Khan (8P20GM103548-02) and
1B01 CA162106A (S.C. Chauhan and M. Jaggi) and the College of Pharmacy
2013 Dean’s Seed Grant of the University of Tennessee Health Science Center
(M. Jaggi and M.M. Yallapu).

The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.

Received August 20, 2014; revised January 29, 2015; accepted February 21,
2015; published OnlineFirst April 3, 2015.
References


Ormeloxifene Suppresses Desmoplasia and Enhances Sensitivity of Gemcitabine in Pancreatic Cancer

Sheema Khan, Mara C. Ebeling, Neeraj Chauhan, et al.


Updated version
Access the most recent version of this article at:
doi:10.1158/0008-5472.CAN-14-2397

Supplementary Material
Access the most recent supplemental material at:
http://cancerres.aacrjournals.org/content/suppl/2015/04/04/0008-5472.CAN-14-2397.DC1

Cited articles
This article cites 49 articles, 19 of which you can access for free at:
http://cancerres.aacrjournals.org/content/75/11/2292.full#ref-list-1

Citing articles
This article has been cited by 3 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/75/11/2292.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://cancerres.aacrjournals.org/content/75/11/2292.
Click on “Request Permissions” which will take you to the Copyright Clearance Center’s (CCC) Rightslink site.